Document is current
Any future updates will be listed below
-
Authors
Bergholz, Johann S. https://orcid.org/0000-0003-4609-8448
Wang, Qiwei https://orcid.org/0000-0003-3897-2529
Wang, Qi
Ramseier, Michelle
Prakadan, Sanjay
Wang, Weihua
Fang, Rong
Kabraji, Sheheryar https://orcid.org/0000-0002-5315-7103
Zhou, Qian
Gray, G. Kenneth
Abell-Hart, Kayley
Xie, Shaozhen
Guo, Xiaocan
Gu, Hao
Von, Thanh
Jiang, Tao
Tang, Shuang
Freeman, Gordon J. https://orcid.org/0000-0002-7210-5616
Kim, Hye-Jung https://orcid.org/0000-0001-5595-4264
Shalek, Alex K. https://orcid.org/0000-0001-5670-8778
Roberts, Thomas M. https://orcid.org/0000-0001-6453-3955
Zhao, Jean J. https://orcid.org/0000-0002-4561-5688
- License Information
-
More Information
Article History
Received: 1 November 2020
Accepted: 10 March 2023
First Online: 19 April 2023
Competing interests
: J.S.B. is a scientific consultant for Geode Therapeutics Inc. J.S.B., G.J.F., T.M.R. and J.J.Z. are co-inventors of DFCI 2180.001 (DFS-166.25) related to this work. Qiwei Wang is a scientific consultant for Crimson Biopharm Inc. Qi Wang is currently an employee at Geode Therapeutics Inc. S.P. is currently an employee at Takeda Pharmaceuticals. S.X. is currently an employee at HiFiBiO Therapeutics. T.V. is currently an employee at MarvelBiome Inc. G.J.F. has patents and pending royalties on the PD-1–PD-L1 pathway from Roche, Merck MSD, Bristol-Myers-Squibb, Merck KGA, Boehringer-Ingelheim, AstraZeneca, Dako, Leica, Mayo Clinic, Eli Lilly and Novartis. G.J.F. has served on advisory boards for Roche, Bristol-Myers-Squibb, Xios, Origimed, Triursus, iTeos, NextPoint, IgM, Jubilant, Trillium, IOME, Geode, Bright Peak, and GV20. G.J.F. has equity in Nextpoint, Triursus, Xios, iTeos, IgM, Trillium, Invaria, Geode and GV20. H.-J.K. is currently an employee at Genentech. A.K.S. has received compensation for consulting and/or SAB membership from Merck, Honeycomb Biotechnologies, Cellarity, Repertoire Immune Medicines, Hovione, Third Rock Ventures, Ochre Bio, FL82, Empress Therapeutics, Relation Therapeutics, Senda Biosciences, IntrECate biotherapeutics, Santa Ana Bio, and Dahlia Biosciences unrelated to this work. T.M.R. is a SAB member for Shiftbio and K2B Therapeutics and is a co-founder of Geode Therapeutics Inc. J.J.Z. is a co-founder and board director of Crimson Biotech Inc. and Geode Therapeutics Inc. All other authors declare no competing interests.
